CMMC Phase 1 began Nov. 10, and major defense primary contractors are already demanding compliance from their suppliers.
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one ...
TIX100 Demonstrates Safety and Tolerability in Human Subjects, Marking a Key Drug Development Milestone Post-Hoc Analysis Reveals Promising First Biological TIX100 Signal in Humans TIXiMED to Advance ...
Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook In the years since, the franchise has changed considerably. The MCU movies of 2025 have brought ...
BOSTON--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the presentation ...
Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results